CA2836599A1 - Process for purifying heparan-n-sulfatase - Google Patents
Process for purifying heparan-n-sulfatase Download PDFInfo
- Publication number
- CA2836599A1 CA2836599A1 CA2836599A CA2836599A CA2836599A1 CA 2836599 A1 CA2836599 A1 CA 2836599A1 CA 2836599 A CA2836599 A CA 2836599A CA 2836599 A CA2836599 A CA 2836599A CA 2836599 A1 CA2836599 A1 CA 2836599A1
- Authority
- CA
- Canada
- Prior art keywords
- hns
- process according
- heparan
- sulfatase
- column
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108010089932 heparan sulfate sulfatase Proteins 0.000 title claims abstract description 232
- 238000000034 method Methods 0.000 title claims description 76
- 230000008569 process Effects 0.000 title claims description 54
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 96
- 108091006629 SLC13A2 Proteins 0.000 claims description 77
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims description 74
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims description 74
- 239000000203 mixture Substances 0.000 claims description 71
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 56
- 229920005989 resin Polymers 0.000 claims description 50
- 239000011780 sodium chloride Substances 0.000 claims description 48
- 239000007983 Tris buffer Substances 0.000 claims description 41
- 239000011347 resin Substances 0.000 claims description 41
- 239000012539 chromatography resin Substances 0.000 claims description 39
- 125000002091 cationic group Chemical group 0.000 claims description 30
- 229920002684 Sepharose Polymers 0.000 claims description 24
- 239000000872 buffer Substances 0.000 claims description 20
- 125000000129 anionic group Chemical group 0.000 claims description 18
- 239000000243 solution Substances 0.000 claims description 15
- 239000000919 ceramic Substances 0.000 claims description 12
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 9
- 239000003480 eluent Substances 0.000 claims description 9
- 239000001632 sodium acetate Substances 0.000 claims description 9
- 235000017281 sodium acetate Nutrition 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 8
- 238000004191 hydrophobic interaction chromatography Methods 0.000 claims description 8
- 239000011159 matrix material Substances 0.000 claims description 8
- 239000012564 Q sepharose fast flow resin Substances 0.000 claims description 4
- 238000011026 diafiltration Methods 0.000 claims description 3
- 238000000108 ultra-filtration Methods 0.000 claims description 3
- VBAOEVKQBLGWTH-UHFFFAOYSA-N 2-pyridin-4-ylethanethiol Chemical compound SCCC1=CC=NC=C1 VBAOEVKQBLGWTH-UHFFFAOYSA-N 0.000 claims description 2
- 241000700605 Viruses Species 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 claims 2
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 claims 2
- 230000000415 inactivating effect Effects 0.000 claims 1
- 238000011210 chromatographic step Methods 0.000 abstract description 13
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 238000011084 recovery Methods 0.000 description 48
- 238000000746 purification Methods 0.000 description 46
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 42
- 238000010828 elution Methods 0.000 description 41
- 238000011068 loading method Methods 0.000 description 34
- 230000000694 effects Effects 0.000 description 25
- 238000004440 column chromatography Methods 0.000 description 21
- 230000003993 interaction Effects 0.000 description 21
- 239000000463 material Substances 0.000 description 21
- 238000005406 washing Methods 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 20
- 230000002209 hydrophobic effect Effects 0.000 description 20
- 102000004190 Enzymes Human genes 0.000 description 18
- 108090000790 Enzymes Proteins 0.000 description 18
- 241000282414 Homo sapiens Species 0.000 description 18
- 238000002965 ELISA Methods 0.000 description 16
- 239000012501 chromatography medium Substances 0.000 description 16
- 208000005340 mucopolysaccharidosis III Diseases 0.000 description 14
- 238000003556 assay Methods 0.000 description 12
- 239000000356 contaminant Substances 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 241001460678 Napo <wasp> Species 0.000 description 11
- 238000002835 absorbance Methods 0.000 description 10
- 238000011067 equilibration Methods 0.000 description 10
- 239000006167 equilibration buffer Substances 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 230000003612 virological effect Effects 0.000 description 9
- 238000005349 anion exchange Methods 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 8
- 239000007858 starting material Substances 0.000 description 8
- 238000011012 sanitization Methods 0.000 description 7
- 108010006140 N-sulfoglucosamine sulfohydrolase Proteins 0.000 description 6
- 102100027661 N-sulphoglucosamine sulphohydrolase Human genes 0.000 description 6
- 238000004587 chromatography analysis Methods 0.000 description 6
- 238000012854 evaluation process Methods 0.000 description 6
- 230000002132 lysosomal effect Effects 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 239000011534 wash buffer Substances 0.000 description 6
- 208000002678 Mucopolysaccharidoses Diseases 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 5
- 239000012149 elution buffer Substances 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 230000002779 inactivation Effects 0.000 description 5
- 206010028093 mucopolysaccharidosis Diseases 0.000 description 5
- HSHNITRMYYLLCV-UHFFFAOYSA-N 4-methylumbelliferone Chemical compound C1=C(O)C=CC2=C1OC(=O)C=C2C HSHNITRMYYLLCV-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 229920002683 Glycosaminoglycan Polymers 0.000 description 4
- 229920002971 Heparan sulfate Polymers 0.000 description 4
- 239000003957 anion exchange resin Substances 0.000 description 4
- 239000013590 bulk material Substances 0.000 description 4
- 239000006143 cell culture medium Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 210000003292 kidney cell Anatomy 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000011535 reaction buffer Substances 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000001488 sodium phosphate Substances 0.000 description 3
- 229910000162 sodium phosphate Inorganic materials 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 3
- DAPOMFMFTBUAKL-UHFFFAOYSA-N 2-ethylpyridine-3-thiol Chemical compound CCC1=NC=CC=C1S DAPOMFMFTBUAKL-UHFFFAOYSA-N 0.000 description 2
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 2
- QYYMDNHUJFIDDQ-UHFFFAOYSA-N 5-chloro-2-methyl-1,2-thiazol-3-one;2-methyl-1,2-thiazol-3-one Chemical compound CN1SC=CC1=O.CN1SC(Cl)=CC1=O QYYMDNHUJFIDDQ-UHFFFAOYSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 208000015439 Lysosomal storage disease Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000011097 chromatography purification Methods 0.000 description 2
- 235000021310 complex sugar Nutrition 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 208000011045 mucopolysaccharidosis type 3 Diseases 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000013014 purified material Substances 0.000 description 2
- -1 rhHNS Proteins 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 206010012559 Developmental delay Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 101000822667 Mus musculus Something about silencing protein 10 Proteins 0.000 description 1
- 101710091062 N-sulphoglucosamine sulphohydrolase Proteins 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 102000005262 Sulfatase Human genes 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 244000000188 Vaccinium ovalifolium Species 0.000 description 1
- WTEDCRZHOZSQII-BTAUDXDXSA-N [(2R,3R,4R,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-2-(4-methyl-2-oxochromen-7-yl)oxyoxan-3-yl]sulfamic acid Chemical compound C1=CC=2C(C)=CC(=O)OC=2C=C1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NS(O)(=O)=O WTEDCRZHOZSQII-BTAUDXDXSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000013584 assay control Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000012045 crude solution Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000011833 dog model Methods 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 239000012156 elution solvent Substances 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N glucosamine group Chemical group OC1[C@H](N)[C@@H](O)[C@H](O)[C@H](O1)CO MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000012616 hydrophobic interaction chromatography medium Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000008140 language development Effects 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 239000006225 natural substrate Substances 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000012521 purified sample Substances 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000000717 sertoli cell Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000002594 sorbent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-M sulfamate Chemical compound NS([O-])(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-M 0.000 description 1
- 108060007951 sulfatase Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 125000003698 tetramethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161488090P | 2011-05-19 | 2011-05-19 | |
| US61/488,090 | 2011-05-19 | ||
| PCT/US2012/038630 WO2012159053A1 (en) | 2011-05-19 | 2012-05-18 | Process for purifying heparan-n-sulfatase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2836599A1 true CA2836599A1 (en) | 2012-11-22 |
Family
ID=47177365
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2836599A Abandoned CA2836599A1 (en) | 2011-05-19 | 2012-05-18 | Process for purifying heparan-n-sulfatase |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20120329133A1 (enExample) |
| EP (2) | EP2929892B1 (enExample) |
| JP (2) | JP2014517692A (enExample) |
| AR (1) | AR086445A1 (enExample) |
| CA (1) | CA2836599A1 (enExample) |
| HK (1) | HK1214960A1 (enExample) |
| TW (1) | TW201307563A (enExample) |
| WO (1) | WO2012159053A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11584777B2 (en) | 2017-08-31 | 2023-02-21 | Green Cross Corporation | Method for purifying a sulfatase protein |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7572619B2 (en) * | 2000-03-22 | 2009-08-11 | Octagene Gmbh | Recombinant blood clotting factors |
| DK1501369T3 (en) * | 2002-04-26 | 2015-09-28 | Genentech Inc | Non-affinity purification of proteins |
| ATE494367T1 (de) * | 2002-12-18 | 2011-01-15 | Hoffmann La Roche | Rekombinante desoxyribonuclease i aus rinder- pankreas mit hoher spezifischer aktivität |
| AU2005211775B2 (en) * | 2004-02-06 | 2009-10-08 | Biomarin Pharmaceutical Inc. | Manufacture of highly phosphorylated lysosomal enzymes and uses thereof |
| SI1828239T1 (sl) * | 2004-12-10 | 2011-11-30 | Zymogenetics Inc | Proizvodnja fgf18 v prokariotskih gostiteljih |
| EP2141178A4 (en) * | 2007-04-02 | 2010-05-19 | Kyowa Hakko Kirin Co Ltd | PROCESS FOR PRODUCING ANTITHROMBIN COMPOSITION |
| EP2245145B1 (en) | 2008-01-18 | 2016-12-14 | BioMarin Pharmaceutical Inc. | Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof |
| CA2805413A1 (en) * | 2010-06-25 | 2011-12-29 | Shire Human Genetic Therapies, Inc. | Methods and compositions for cns delivery of heparan n-sulfatase |
-
2012
- 2012-05-17 TW TW101117561A patent/TW201307563A/zh unknown
- 2012-05-18 EP EP15166651.8A patent/EP2929892B1/en active Active
- 2012-05-18 CA CA2836599A patent/CA2836599A1/en not_active Abandoned
- 2012-05-18 JP JP2014511591A patent/JP2014517692A/ja not_active Ceased
- 2012-05-18 AR ARP120101760A patent/AR086445A1/es unknown
- 2012-05-18 WO PCT/US2012/038630 patent/WO2012159053A1/en not_active Ceased
- 2012-05-18 US US13/475,568 patent/US20120329133A1/en not_active Abandoned
- 2012-05-18 EP EP12785579.9A patent/EP2709654A4/en not_active Withdrawn
-
2016
- 2016-03-15 HK HK16102969.5A patent/HK1214960A1/en unknown
- 2016-11-01 JP JP2016214041A patent/JP2017029170A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012159053A1 (en) | 2012-11-22 |
| TW201307563A (zh) | 2013-02-16 |
| US20120329133A1 (en) | 2012-12-27 |
| JP2017029170A (ja) | 2017-02-09 |
| HK1214960A1 (en) | 2016-08-12 |
| EP2709654A1 (en) | 2014-03-26 |
| EP2929892A1 (en) | 2015-10-14 |
| EP2709654A4 (en) | 2014-11-12 |
| AR086445A1 (es) | 2013-12-11 |
| EP2929892B1 (en) | 2018-07-04 |
| JP2014517692A (ja) | 2014-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12492390B2 (en) | Methods of purifying recombinant ADAMTS13 and other proteins and compositions thereof | |
| JP7407161B2 (ja) | アリールスルファターゼａの精製方法 | |
| US20230159585A1 (en) | Egg white processing | |
| JP4772905B2 (ja) | アンチトロンビン組成物の製造方法 | |
| EP2929892B1 (en) | Process for purifying heparan-n-sulfatase | |
| US11584777B2 (en) | Method for purifying a sulfatase protein | |
| TWI880351B (zh) | 純化乙醯肝素-n-硫酸酯酶的新方法 | |
| HK40103492B (en) | Methods of purifying recombinant adamts13 and other proteins and compositions thereof | |
| HK40103492A (en) | Methods of purifying recombinant adamts13 and other proteins and compositions thereof | |
| HK1241929A1 (en) | Methods of purifying recombinant adamts13 and other proteins and compositions thereof | |
| HK1241929B (en) | Methods of purifying recombinant adamts13 and other proteins and compositions thereof | |
| AU2018201646A1 (en) | Method for Purifying Recombinant ADAMTS13 and Other Proteins and Compositions Thereof | |
| HK1171784A (en) | Method for purifying recombinant adamts13 and other proteins and compositions thereof | |
| HK1171784B (en) | Method for purifying recombinant adamts13 and other proteins and compositions thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20180518 |